ClinicalTrials.gg
RecruitingNCT07317271VIBEUpdated Mar 5, 2026

VR-PMR for Post-Burn Symptoms

An interventional study of Virtual Reality-Enhanced Progressive Muscle Relaxation and Standard Progressive Muscle Relaxation in Burn, Chronic Pain Following Thermal Burn Injury and Non-Pharmacological Interventions, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors.

The main questions it aims to answer are:

  • Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR?
  • Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors?

Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors.

Participants will:

  • Complete home-based sessions of VR-enhanced PMR
  • Complete home-based sessions of standard PMR
  • Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study
  • Use VR equipment provided for the intervention period (during the VR-PMR arm)
Read the detailed description

Serious burn injuries are a devastating form of trauma, often resulting in long-term physical and psychological challenges. Burn survivors experience a host of burdensome and co-occurring chronic symptoms post-burn injury that affect quality of life and recovery. Among the most prevalent are pain, pruritis (itch), anxiety, sleep disturbances, and fatigue. Despite a decrease in intensity over time, these symptoms often persist well-beyond the initial burn injury and negatively impact recovery, activities of daily living, social participation, and quality of life. Research indicates that these symptoms often co-occur and demonstrate bidirectional relationships. For instance, pain and itch can contribute to sleep disturbances, while anxiety and fatigue can worsen overall itch and pain perception. A reciprocal relationship between sleep and pain after burn injuries has been demonstrated in a number of studies suggesting that pain contributes to poor sleep, and that disruptions in sleep are associated with increased pain and increased use of analgesics.

Pharmacologic interventions for these symptoms, such as the use of opioids or sedatives, can have adverse effects, including dependence, side effects, and inadequate long-term relief. Given the limitations of pharmacologic interventions, non-pharmacologic therapies, such as cognitive-behavioral therapy (CBT), mindfulness, and relaxation techniques, have gained recognition as effective strategies for symptom management in this population. However, CBT, often regarded as the gold standard intervention for improving sleep and pain, has its own barriers, including the need for trained professionals, high costs, and challenges related to patient adherence. These barriers underscore the need for cost-effective, accessible, and effective self-administered approaches that can be easily integrated into everyday life of burn survivors.

Progressive muscle relaxation (PMR) is a well-established mind-body relaxation technique that has been shown to reduce stress, anxiety, pain, and itch, and improve sleep by systematically tensing and relaxing different muscle groups. Recent advancements in virtual reality (VR) technology present an opportunity to enhance the delivery of PMR by creating immersive environments that promote relaxation and improve therapeutic outcomes. VR has previously been used to enhance existing therapies to help improve engagement and therapeutic by providing an immersive environment that complements the therapy. It has been shown to provide pain relief and reduce anxiety in various clinical settings and populations, such as burn care, procedural pain, and chronic pain management. VR is hypothesized to facilitate a more realistic and relaxing sensory experience and has the potential to amplify the effects of PMR by providing additional relaxing auditory and visual stimuli.

This study would leverage novel VR technology to enhance a well-established mind-body intervention, PMR, to support symptom management in a burn population. While the combination of VR and PMR has been explored in a variety of pain populations, its effect on chronic pain, anxiety, itch, sleep, and fatigue have yet to be explored in a burn population. Therefore, this proposed study seeks to evaluate the use of a novel self-administered VR-enhanced PMR (VR-PMR) therapy delivered at-home for symptom management in burn survivors. The aims for this study are as follows:

Aim 1. Determine the feasibility of an at-home, self-administered VR-enhanced PMR (VR-PMR) and PMR intervention in burn survivors.

Aim 1a. Recruitment, enrollment, retention rates, and intervention adherence of participants will be recorded and used to help determine feasibility of the VR-PMR intervention.

Aim 1b. Usability of VR-PMR intervention will be measured with surveys and open-ended prompts for additional qualitative feedback.

Aim 2. Evaluate the preliminary efficacy of VR-PMR and standard PMR interventions on symptom outcomes, including pain severity, itch severity, anxiety, sleep quality, and fatigue, using a within-subject crossover design.

Aim 2a. Compare changes in symptom outcomes across both intervention phases to identify any differential effects.

Aim 2b. Assess the presence of any carryover effects between intervention phases and the potential impact on outcome measures.

02

Conditions studied

  • Burn
  • Chronic Pain Following Thermal Burn Injury
  • Non-Pharmacological Interventions
  • Virtual Reality
  • Sleep Disturbance
  • Anxiety
  • Depressive Symptoms
  • Fatigue Symptom
  • Pruritus
  • Burn Injury
  • Progressive Muscle Relaxation

Keywords

  • Virtual Reality
  • Burn Survivors
  • Progressive Muscle Relaxation
  • Chronic Symptom Management
  • Pain
  • Itch
  • Sleep
  • Fatigue
  • Burns
  • Burn Injury
03

In context

Burns

905 studies on the registry are indexed under Burns; 164 are open to participants now.

This study's planned enrollment of 34 is below the median of 40 across 663 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.

Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old;
  • sustained a burn injury in the last 6 months or longer;
  • Score high on at least one of the following: Insomnia severity index (ISI) score of ≥8, Brief Pain Inventory Short Form (BPI-SF) Pain severity score of ≥3, or PROMIS Itch Severity of ≥55;
  • own a smartphone or computer with reliable internet connection for online visits and survey completion;
  • able to comfortably wear goggles or headsets on face as determined by self-report.

Exclusion criteria

Exclusion criteria:

  • Cognitive impairment (Mini Mental Status Exam () \< 25);
  • history of motion sickness, photosensitivity, photoinduced seizures, and claustrophobia as determined by self-report;
  • uncorrected visual or hearing impairments as determined by self-report;
  • non-English speaker.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    VR-PMR

    Behavioral: Virtual Reality-Enhanced Progressive Muscle Relaxation

  • Active comparator
    PMR

    Behavioral: Standard Progressive Muscle Relaxation

Interventions

  • BehavioralVirtual Reality-Enhanced Progressive Muscle Relaxation

    The VR-PMR intervention is a self-administered 20-minute session, conducted for 3 consecutive days, one hour before bedtime. PMR, participants will tighten and relax specific muscle groups in sequence from the upper body to the lower body then vice versa. While taking deep breaths inhaling through the nose and exhaling through the mouth, patients will be asked to first tense a muscle tightly and hold for slow count of 5 seconds and then relax quickly and completely for 10 seconds until all the tightness and pain flow out of the muscles. During PMR, participants will be immersed in a relaxing, nature-based VR environment. The VR component will use the Quest 3 Headset. Participants will be immersed in a virtual nature walk with accompanying relaxing music and nature sounds. Participants will be given a choice of three 360 nature walk videos set in forests or a beach. Audio instructions for PMR will play over the video's audio. Participants will use the participant's own smartphone.

  • BehavioralStandard Progressive Muscle Relaxation

    Standard progressive muscle relaxation (PMR) therapy delivered via audio-recorded guides. For PMR, participants will tighten and relax specific muscle groups in sequence from the upper body to the lower body then vice versa. While taking deep breaths inhaling the nose and exhaling through the mouth, patients will be asked to first tense a muscle tightly and hold for slow count of 5 seconds and then relax quickly and completely for 10 seconds until all the tightness and pain flow out of the muscles.

06

What researchers measure

Primary outcomes

  1. Pain Intensity as assessed by the the Numeric Rating Scale (NRS).

    Pain will be measured using the the Numeric Rating Scale (NRS). Scale range 0-10, higher score worse pain severity.

    Time frame: pre intervention and post VR-PMR intervention (3 weeks)

  2. Itch Intensity as assessed by the the Numeric Rating Scale (NRS)

    Itch intensity pre- and post-intervention will be measured using the the Numeric Rating Scale (NRS). Scale range 0-10, higher score worse itch severity.

    Time frame: pre intervention and post VR-PMR intervention (3 weeks)

  3. Anxiety as assessed by the Numeric Rating Scale

    Anxiety severity pre- and post-intervention will be measured using the Numeric Rating Scale. Total score range from 0-10 with higher scores indicating worse anxiety.

    Time frame: Pre intervention, post VR-PMR intervention (3 weeks)

Secondary outcomes

  1. Quality of Life (Burn Specific Health Scale Brief)

    The Burn Specific Health Scale Brief (BSHS-B) will assess quality of life pre- and post-intervention. The BSHS-B consists of 40-items with 9 subscales that measure physical and psychosocial aspects of burn recovery. Total score range 0-160 (sum of score for all items) higher score suggests better quality of life.

    Time frame: pre intervention and post intervention (3 weeks)

  2. Sleep Disturbances as assessed by the PROMIS Sleep Disturbance Scale

    The PROMIS Sleep Disturbance scale will be used to measure pre- and post-intervention sleep quality. T score mean = 50, SD = 10 Higher scores indicate worse symptoms.

    Time frame: pre intervention and post intervention (3 weeks)

  3. Total Sleep Time (TST)

    Total sleep time (minutes) derived from actigraphy and sleep diary data.

    Time frame: pre intervention and post intervention (3 weeks)

  4. Wake After Sleep Onset (WASO)

    Derived from actigraphy and sleep diary data.

    Time frame: pre intervention and post intervention (3 weeks)

  5. Sleep Latency

    Derived from actigraphy and sleep diary data. Amount of time measured in minutes it takes to fall asleep.

    Time frame: pre intervention and post intervention (3 weeks)

  6. Sleep Efficiency

    Derived from actigraphy and sleep diary data. Percentage total sleep time divided by time in bed.

    Time frame: pre intervention and post intervention (3 weeks)

  7. Fatigue as assessed by the Multidimensional Fatigue Inventory

    Fatigue will be measured using the Multidimensional Fatigue Inventory (MFI) at baseline and at the end of the PMR sessions. The MFI is a 20-item scale designed to evaluate 5 dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue. Scores on each subscale range 4-20. Total score range 20 to 100; higher the score worse fatigue.

    Time frame: pre intervention and post intervention (3 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 210 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 10 months is below that.

Counting every sponsor, half of 239 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 5, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07317271
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Feb 27, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Lynn Nakad, PhD, RN
Contact
lnakad1@jhmi.edu
410-550-9056
Sheera Lerman Zohar, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion